Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats

[1]  D. Faller,et al.  Arginine butyrate-induced susceptibility to ganciclovir in an Epstein-Barr-virus-associated lymphoma. , 1998, Blood cells, molecules & diseases.

[2]  E. Sausville,et al.  Phase I Study of the Orally Administered Butyrate Prodrug, Tributyrin, in Patients with Solid Tumors1 , 2022 .

[3]  M. Heymann,et al.  5‐fluorouracil‐resistant colonic tumors are highly responsive to sodium butyrate/interleukin‐2 bitherapy in rats , 1997, International journal of cancer.

[4]  Y. Honma,et al.  Enhancement of sensitivity of human lung adenocarcinoma cells to growth-inhibitory activity of interferon alpha by differentiation-inducing agents. , 1996, British Journal of Cancer.

[5]  N. Olivieri,et al.  Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. , 1995, The New England journal of medicine.

[6]  Zi X. Chen,et al.  Tributyrin: a prodrug of butyric acid for potential clinical application in differentiation therapy. , 1994, Cancer research.

[7]  D. Samid,et al.  Enhanced fetal hemoglobin production by phenylacetate and 4- phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia , 1993 .

[8]  J. Lupton,et al.  Modulation of colonic epithelial cell proliferation, histone acetylation, and luminal short chain fatty acids by variation of dietary fiber (wheat bran) in rats. , 1992, Cancer research.

[9]  D. Samid,et al.  Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. , 1992, The New England journal of medicine.

[10]  G. Ronco,et al.  Enhancement by stable butyrate derivatives of antitumor and antiviral actions of interferon , 1992, International journal of cancer.

[11]  Thomas M. Ludden,et al.  Nonlinear Pharmacokinetics , 1991, Clinical pharmacokinetics.

[12]  A. Novogrodsky,et al.  Sodium butyrate enhances the activities of membranal enzymes and increases drug sensitivity in a cell line from ascitic fluid of an ovarian carcinoma patient. , 1989, European journal of cancer & clinical oncology.

[13]  R B Smith,et al.  An evaluation of population pharmacokinetics in therapeutic trials. Part III. Prospective data collection versus retrospective data assembly , 1989, Clinical pharmacology and therapeutics.

[14]  I. Tardivel,et al.  Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salts. , 1989, Clinica chimica acta; international journal of clinical chemistry.

[15]  G. Stamatoyannopoulos,et al.  alpha-Amino-N-butyric acid stimulates fetal hemoglobin in the adult. , 1988, Blood.

[16]  L. Burns,et al.  Butyrate induces selective transcriptional activation of a hypomethylated embryonic globin gene in adult erythroid cells. , 1988, Blood.

[17]  S. J. Chen,et al.  Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[18]  E. Kurschel,et al.  Clinical pharmacology of sodium butyrate in patients with acute leukemia. , 1987, European journal of cancer & clinical oncology.

[19]  T. Grasela,et al.  An evaluation of population pharmacokinetics in therapeutic trials. Part I. Comparison of methodologies , 1986, Clinical pharmacology and therapeutics.

[20]  A. Clifford,et al.  Effects of dietary triglycerides on serum and liver lipids and sterol excretion of rats. , 1986, The Journal of nutrition.

[21]  W J Jusko,et al.  LAGRAN program for area and moments in pharmacokinetic analysis. , 1983, Computer programs in biomedicine.

[22]  K. Prasad,et al.  Butyric acid: a small fatty acid with diverse biological functions. , 1980, Life sciences.

[23]  A Schumitzky,et al.  A program package for simulation and parameter estimation in pharmacokinetic systems. , 1979, Computer programs in biomedicine.

[24]  H. Akaike.  A new look at the statistical model identification , 1974 .

[25]  Y. Honma,et al.  An anti-cancer derivative of butyric acid (pivalyloxmethyl buterate) and daunorubicin cooperatively prolong survival of mice inoculated with monocytic leukaemia cells. , 1997, British Journal of Cancer.

[26]  Zhi-Min Yuan,et al.  Plasma pharmacokinetics and urinary excretion of the polyamine analogue 1, 19-bis(ethylamino)-5, 10, 15-triazanonadecane in CD2F1 mice , 1996, Cancer Chemotherapy and Pharmacology.

[27]  A. Ravid,et al.  Effect of polar organic compounds on leukemic cells: Butyrate‐induced partial remission of acute myelogenous leukemia in a child , 1983, Cancer.